Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands
In conclusion, this nation-wide study provides valuable insights into the healthcare costs of advanced cutaneous melanoma patients who were treated with ipilimumab in clinical practice. Most of the costs were attributable to ipilimumab, but the costs and its distribution varied considerably across subgroups.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
More News: Cancer | Cancer & Oncology | Healthcare Costs | Melanoma | Netherlands Health | Skin Cancer | Study | Yervoy